Kiora Pharmaceuticals (KPRX) Assets Average (2015 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Assets Average came in at $22.7 million in Q1 2026, down 35.49% YoY from $35.3 million in Q1 2025, and down 15.96% on a QoQ basis from $27.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Assets Average (2015 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 12 years of Assets Average data on file, last reported at $22.7 million in Q1 2026.
- Quarterly Assets Average fell 35.49% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.7 million (down 35.49% YoY) and the FY2025 annual result came in at $30.4 million, up 21.0% from the prior year.
- Assets Average eased to $22.7 million in Q1 2026, from $27.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $41.6 million in Q2 2024 to a low of $14.8 million in Q4 2023.
- A 5-year average of $25.6 million and a median of $22.7 million in 2026 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average surged 153.29% — and 2026, when it tumbled 35.49%.
- Tracing KPRX's Assets Average over 5 years: stood at $18.2 million in 2022, then declined by 18.53% to $14.8 million in 2023, then surged by 153.29% to $37.5 million in 2024, then retreated by 27.84% to $27.1 million in 2025, then dropped by 15.96% to $22.7 million in 2026.
- The last three Assets Average figures came in at $22.7 million (Q1 2026), $27.1 million (Q4 2025), and $30.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.50 Mn |
| Mar 31, 2026 | 22.74 Mn |
| Dec 31, 2025 | 27.06 Mn |
| Sep 30, 2025 | 30.90 Mn |
| Jun 30, 2025 | 32.98 Mn |
| Mar 31, 2025 | 35.25 Mn |
| Dec 31, 2024 | 37.50 Mn |
| Sep 30, 2024 | 39.66 Mn |
| Jun 30, 2024 | 41.63 Mn |
| Mar 31, 2024 | 28.08 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 17.89 Mn |
| Jun 30, 2023 | 18.21 Mn |
| Mar 31, 2023 | 17.60 Mn |
| Dec 31, 2022 | 18.17 Mn |
| Sep 30, 2022 | 16.56 Mn |
| Jun 30, 2022 | 16.55 Mn |
| Mar 31, 2022 | 18.88 Mn |
| Dec 31, 2021 | 22.81 Mn |
| Sep 30, 2021 | 21.87 Mn |